Adverse events231

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 231

Type	Event	Organ system	Group	Affected	At risk
other	Injection Site Induration	General disorders	Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation	40	1,429
other	Injection Site Induration	General disorders	Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation	14	504
other	Injection Site Induration	General disorders	Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation	6	512
other	Injection Site Pain	General disorders	Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation	127	1,429
other	Injection Site Pain	General disorders	Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation	12	504
other	Injection Site Pain	General disorders	Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation	14	512
other	Nasopharyngitis	Infections and infestations	Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation	66	1,429
other	Nasopharyngitis	Infections and infestations	Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation	36	504
other	Nasopharyngitis	Infections and infestations	Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation	33	512
other	Weight Decreased	Investigations	Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation	10	1,429
other	Weight Decreased	Investigations	Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation	14	504
other	Weight Decreased	Investigations	Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation	14	512
other	Weight Increased	Investigations	Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation	64	1,429
other	Weight Increased	Investigations	Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation	105	504
other	Weight Increased	Investigations	Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation	109	512
other	Akathisia	Nervous system disorders	Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation	78	1,429
other	Akathisia	Nervous system disorders	Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation	20	504
other	Akathisia	Nervous system disorders	Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation	14	512
other	Headache	Nervous system disorders	Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation	46	1,429
other	Headache	Nervous system disorders	Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation	18	504

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01515423/events

API reference For AI assistants

Adverse events231

Sources 3

Read this list from software.